Mats Blom

Mats Blom has extensive managerial experience and has held CFO positions in several public and non-public companies. He has served as CFO of Zealand Pharma A/B, a biotechnology company dual listed at Nasdaq in New York and Copenhagen, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has been CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.